secwatch / observer
8-K filed January 30, 2025, 6:59 PM ET CIK 0000727207
regulatory confidence high sentiment negative materiality 0.75

Nasdaq warns Accelerate Diagnostics of potential delisting due to MVLS below $35M

Accelerate Diagnostics, Inc

item 3.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001104659-25-007311
form_type
8-K
ticker
null
cik
0000727207
company_name
Accelerate Diagnostics, Inc
filed_at
2025-01-30T23:59:59+00:00
discovered_at
2026-05-14T18:03:06.206468+00:00
generated_at
2026-05-27T06:03:47.850532+00:00
sec_items
["3.01"]
event_type
regulatory
sentiment
negative
materiality_score
0.75
calibrated_materiality_score
0.75
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001104659-25-007311
json_url
https://secwatch.observer/filing/0001104659-25-007311.json
markdown_url
https://secwatch.observer/filing/0001104659-25-007311.md
text_url
https://secwatch.observer/filing/0001104659-25-007311.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/727207/000110465925007311/0001104659-25-007311-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/727207/000110465925007311/tm254764d1_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

42bec1b084ba666107cfcbfd2c0a4b3cee6906ed

Accelerate Diagnostics, Inc received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

ILLR

Triller gets Nasdaq bid-price exception until June 30, 2026

Triller Group Inc. June 2, 2026, 8:26 AM ET regulatory Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

Comparable filing

May 29, 2026, the Nasdaq Hearings Panel (the “Panel”) notified Triller Group Inc. (“Triller” or the “Company”) that the Panel determined to grant Triller an exception to the Listing Rules of The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) until June 30, 2026 in order to regain compliance with Listing Rule 5550(a)(2) (the “Bid Price Rule”). As previously disclosed on April 24, 2026, following a successful appeal by the Company to the Nasdaq Stock Market Listing and Hearing Review Council (the “Listing Council”) which modified a previous December 26, 2025 decision by a Nasdaq Hearings Panel

Filing page SEC filing

ISPC

iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum

iSpecimen Inc. June 1, 2026, 5:00 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

Comparable filing

May 29, 2026, iSpecimen Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May 29, 2026, the Company doe

Filing page SEC filing

GENC

Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing

GENCOR INDUSTRIES INC June 1, 2026, 4:09 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

Comparable filing

May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY

Filing page SEC filing

NUTR

NusaTrip receives Nasdaq delinquency notice for late 10-K and 10-Q; faces delisting if not compliant by Oct 12, 2026

NUSATRIP Inc June 1, 2026, 7:10 AM ET regulatory Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

Comparable filing

May 27, 2026, NusaTrip Incorporated (the “Company”) received a delinquency notification letter (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the period ended December 31, 2025 and its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (collectively, the “Delinquent Filings”). The Listing Rule requires listed companies to timely file all req

Filing page SEC filing

HWH

HWH International receives Nasdaq deficiency notice for equity below $2.5M threshold

HWH International Inc. May 29, 2026, 5:21 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

Comparable filing

May 29, 2026 HWH International Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) because the Company’s stockholders’ equity of $2,078,220 as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026 was below the required minimum of $2.5 million, and because, as of May 29, 2026, the Company did

Filing page SEC filing

ATNM

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc. May 29, 2026, 5:10 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

Comparable filing

May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately

Filing page SEC filing

CSAI

Cloudastructure receives Nasdaq delinquency notice for late Q1 10-Q filing

CLOUDASTRUCTURE, INC. May 29, 2026, 5:09 PM ET regulatory Items 3.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

Comparable filing

May 26, 2026, Cloudastructure, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (“Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. The Company requires additional time to review and confirm the accounting treatment for its outstand

Filing page SEC filing

EDBL

Edible Garden receives Nasdaq delisting notice for bid price non-compliance; intends to appeal

Edible Garden AG Inc May 29, 2026, 5:00 PM ET regulatory Items 3.01

same fact type: exchange_compliance_notice same SEC item: 3.01 same event type: regulatory similar materiality

This filing

January 28, 2025, Accelerate Diagnostics, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company t

Comparable filing

May 27, 2026, Edible Garden AG Incorporated (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for at least 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of at least $1 per share (the “Bid Price Rule”). Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), because the Company has effected a reverse stock split over the prior one-year per

Filing page SEC filing

Source: SEC EDGAR
accession 0001104659-25-007311
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.